Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Sequenom; Iverson Genetic Diagnostics; Eppendorf; Ariadne; Vermont Genetics Legislation

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Sequenom this week said that it has awarded non-qualified stock option grants for a total of 74,450 shares of common stock to six new employees under the firm's New Hire Equity Incentive Plan. The firm said 14,450 of the shares have an exercise price of $6.14, which was equal to the closing price of Sequenom's common stock on Feb. 28, and 60,000 shares have a price of $6.39, the closing price of its common stock on Feb. 15, the dates the options were granted.


Iverson Genetic Diagnostics has launched an 18-month study to assess the utility of genetic testing in determining the proper warfarin dose for individual patients. Data from the study will be used by the Centers for Medicare & Medicaid Services to help determine whether to provide insurance reimbursement for a genetic warfarin test. The Bothell, Wash.-based firm announced last summer that it had received CMS approval to conduct the study, which is anticipated to involve more than 7,000 participants at more than 50 sites across the country.


Eppendorf said this week that the Genome Center at Washington University has purchased 10 of the firm's epMotion 5075 TMX PC systems for sample preparation needs on the Illumina GAIIx and HiSeq platforms. The firm did not disclose financial details of the bulk order.


Ariadne said today that the National Cancer Institute has renewed its license for site-wide use of the firm's Pathway Studio Enterprise system that includes the ResNet Mammalian database and Ariadne MedScan text processing technology.


Vermont has become the third state this year to introduce genetic privacy legislation. The state follows efforts in California and Massachusetts to enhance protections on and privacy of individual genetic information beyond that provided by the national Genetic Information Nondiscrimination Act of 2008 and protections already established in part by the state's courts.

"The three bills are not carbon copies of one another, but they do reflect a belief that certain values are universal," Steve May, executive director of the Forum on Genetic Equity, said in a statement this week. "Chief among these is the idea that individuals need to be able to exert control and make decisions about their own genetic information, genetic material and genetic privacy."

The Vermont bill can be found here.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.